T-1105 (T1105), an analog of T-705 (favipiravir), is a novel and potent broad-spectrum antiviral inhibitor that inhibits the polymerases of RNA viruses after being converted to the actiive form: ribonucleoside triphosphate (RTP) metabolite. T-1105 has a broad spectrum of antiviral activity against various RNA viruses, including Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), and foot-and-mouth disease virus (FMDV).
Physicochemical Properties
| Molecular Formula | C5H5N3O2 |
| Molecular Weight | 139.114 |
| Exact Mass | 139.038 |
| Elemental Analysis | C, 43.17; H, 3.62; N, 30.21; O, 23.00 |
| CAS # | 55321-99-8 |
| Related CAS # | Favipiravir;259793-96-9 |
| PubChem CID | 294642 |
| Appearance | Off-white to light brown solid powder |
| Density | 1.5±0.1 g/cm3 |
| Boiling Point | 640.8±55.0 °C at 760 mmHg |
| Melting Point | ca 270℃ |
| Flash Point | 341.3±31.5 °C |
| Vapour Pressure | 0.0±2.0 mmHg at 25°C |
| Index of Refraction | 1.634 |
| LogP | 0.32 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 1 |
| Heavy Atom Count | 10 |
| Complexity | 241 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(C1=NC=CN=C1O)N |
| InChi Key | SZPBAPFUXAADQV-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C5H5N3O2/c6-4(9)3-5(10)8-2-1-7-3/h1-2H,(H2,6,9)(H,8,10) |
| Chemical Name | 3-oxo-3,4-dihydropyrazine-2-carboxamide |
| Synonyms | T 1105; T1105. |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | parainfluenza-3 virus（EC50= 17 μM）;Punta Toro virus（EC50= 24 μM）;ZIKV strain SZ01（EC50= 97.5 μM） |
| ln Vitro |
Zika virus (ZIKV), influenza virus, arenaviruses, bunyaviruses, West Nile virus (WNV), yellow fever virus (YFV), foot-and-mouth disease virus (FMDV), and other RNA viruses are all susceptible to T-1105's antiviral activity[1][2]. T-1105 exhibits strong anti-RNA virus activity against the parainfluenza-3 virus and the Punta Toro virus in MDCK cells, with EC50 values of 17 μM and 24 μM, respectively[3]. One possible inhibitor of the Zika virus's replication is T-1105[4]. T-1105 does not affect cell viability at concentrations of 0–3 μM, but it can inhibit SFTSV replication in Vero cells with an IC50 of 49 μM[5]. |
| ln Vivo | T-1105 (200 mg/kg, twice day for 6 days) effectively prevents the virus from replicating in infected pigs[6]. |
| Cell Assay |
Cell Line: Vero cells Concentration: 0-3 μM Incubation Time: 4 h Result: Did not affect cell viability in the test range (0-3 μM). |
| Animal Protocol |
Animal Model: Pigs[6] Dosage: 200 mg/kg Administration: Oral, 200 mg/kg, twice daily for 6 days Result: decreased viremia and elevated anti-FMD antibody titers, but no clinical indications of FMD were seen. |
| References |
[1]. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5. [2]. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. [3]. Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). Antiviral Res. 2019 Jul;167:1-5. [4]. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication. Arch Virol. 2017 Sep;162(9):2847-2853. [5]. Efficacy of T-705 (Favipiravir) in the Treatment of Infections with Lethal Severe Fever with Thrombocytopenia Syndrome Virus. [6]. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95-102. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~25 mg/mL (~179.71 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (17.97 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 2.5 mg/mL (17.97 mM) (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1886 mL | 35.9428 mL | 71.8856 mL | |
| 5 mM | 1.4377 mL | 7.1886 mL | 14.3771 mL | |
| 10 mM | 0.7189 mL | 3.5943 mL | 7.1886 mL |